Pacira Pharma (PCRX) Misses Q1 EPS by 15c

Pacira Pharma (NASDAQ: PCRX) reported Q1 EPS of ($0.19), $0.15 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $69.3 million versus the consensus estimate of $70.24 million.

For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Cerebras Q1 EPS miss sends shares down 9% after-hours
• MSCI acquires First Street for $120M to expand climate risk data